An interview with Lars Sørensen, chief executive officer (CEO) of the
pharmaceutical firm Novo Nordisk, is presented. When asked about
diversification, he states that he learned from the company's failed
attempt to enter the glucose monitoring sector that it is best to focus
on one area in which you can excel. Details on the firm's strategy of
selling both generic and differentiated products are presented.
Corporate social responsibility is also discussed.